FDA Accepts Application for Frontline Nivolumab/Ipilimumab in TMB-High NSCLC
Pharma & biotech2018-06-21
7 Views
The FDA has accepted a supplemental biologics license application for the combination of nivolumab plus ipilimumab for the frontline treatment of patients with advanced non–small cell lung cancer with tumor mutational burden ≥10 mutations per megabase.
Source: OncLive
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
